Safety and efficacy of pemafibrate (Parmodia) for patients having dyslipidemia and non-alcoholic fatty liver disease (NAFLD)
Not Applicable
Recruiting
- Conditions
- Patients with dyslipidemia and non-alcoholic fatty liver disease (NAFLD)
- Registration Number
- JPRN-UMIN000035248
- Lead Sponsor
- Shinshu University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1. Creatinine > 1.5 mg/dL 2. Past history of myopathy and renal dysfunction by fibrate drugs 3. During Pregnancy and breast-feeding 4. Humans who were judged as not-suitable for this trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method